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retrospective analysis of a
UK population of 385 pa-
tients, treated with national
guidance, and report patterns
and predictors of failure. Our
guidance results in a negli-
gible regional relapse rate in
areas with no disease at
outset, with a high relapse at
the primary site. Our study
supports efforts to maximize
local disease management in
the post intensity modulated
radiation therapy era.of UK IMRT guidance from February 2013 to October 31, 2017. Collected data
included baseline demographics, treatment details, tumor control, sites of relapse,
and overall survival. Statistical analysis to calculate outcomes and predictive factors
for outcome measures were performed using SPSS and R.
Results: The medical records of 385 consecutive patients were analyzed. Median
follow-up was 24.0 months. Within 6 months of completing CRT, 86.7% of patients
achieved a complete response. Three-year disease-free survival and overall survival
were 75.6% and 85.6%, respectively. Of all relapses, 83.4% occurred at the site of pri-
mary disease. There were 2 isolated relapses in regional nodes not involved at outset.
Predictive factors for cancer recurrence included male sex, high N-stage, and failure to
complete radiation therapy as planned.
Conclusions: The treatment results compare favorably to published outcomes from
similar cohorts using 3-dimensional conformal CRT. The observed patterns of failure
support the current UK IMRT voluming guidelines and dose levels, highlighting our
prophylactic nodal dose as sufficient to prevent isolated regional relapse in uninvolved
nodes. Further investigation of strategies to optimize CR should remain a priority in
ASCC because the site of primary disease remains the overwhelming site of relapse.
 2019 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Anal squamous cell carcinoma (ASCC) is an uncommon
malignancy, with an annual incidence of approximately
8500 in the United States and 1500 in the United
Kingdom.1-4 Chemoradiation therapy (CRT) with concur-
rent mitomycin-c and 5-fluorouracil has been established as
the standard of care after 6 large international trials.5-12
In the last decade, there has been increasing use of in-
tensity modulated radiation therapy (IMRT).13-17 Various
protocols have been developed internationally, with dif-
ferences in doses, volumes, and constraints.18-21 The UK
IMRT guidance was derived from the principles of the UK
ACT2 phase 3 trial.21 UK IMRT demonstrated improved
toxicity and overall treatment time compliance compared
with 3-dimensional (3D) conformal radiation therapy (RT)
treatment in a large national audit.22 There have been some
small iterations; however, the guidance remains very
similar to that at conception in February 2013.
The transition from 3D conformal RT to IMRT presents
a number of challenges. Radiation Therapy Oncology
Group (RTOG) 0529, a single-arm phase 2 trial investi-
gating the toxicity of IMRT in ASCC, included pretreat-
ment quality assurance on all RT treatment plans and
reported a replanning rate of 81%.14 In addition, the lack of
data on relapse patterns and the difference in current atlases
highlight the potential for further data to inform and
improve delineation guidelines. Lastly, the prophylactic
nodal dose was previously delivered in doses of 1.8 to 2 Gy/
fraction for the first phase of the CRT. With the develop-
ment of IMRT protocols, the prophylactic dose is delivered
throughout RT in smaller doses per fraction. The optimal
prophylactic dose is unknown.
The goal of this study was to determine the patterns and
predictors of failure after IMRT delivery in ASCC, inaddition to quantifying the core outcome measures for
ASCC in this group, and to inform routine practice and
guidelines while potentially highlighting areas of interest
for future research and development.
Methods and Materials
Patients
Medical records were retrospectively reviewed for pa-
tients with anal canal and anal margin squamous cell
carcinoma who underwent definitive RT using an IMRT
technique from February 2013 to February 2018 in 5 UK
Cancer Centres: Oxford Cancer and Haematology Centre,
Leeds Cancer Centre, Queen Elizabeth Hospital, Bir-
mingham; Sussex Cancer Centre, Brighton and Velindre
Cancer Centre, Cardiff. Routine diagnostic imaging over
this timeframe was magnetic resonance imaging (MRI) of
the pelvis and computed tomography (CT) of the chest,
abdomen, and pelvis. The use of positron emission to-
mography (PET) was heterogeneous, with 1 center using
it for all T2 patients, 3 using it in patients with staging
discrepancies, and the last having no access. This study
only included patients of sufficiently high risk to merit
prophylactic nodal irradiation. Therefore, selected good-
prognosis patients (T1 N0, well differentiated pathology,
female patients, anal verge rather than canal) who un-
derwent involved field radiation alone were excluded.
Those with metastatic disease at diagnosis were excluded.
A standardized datasheet was developed and piloted by
3 centers. All centers used local electronic systems to
identify all sequential ASCC undergoing RT during this
timeframe and screened for eligibility. Data on patient,
disease and treatment characteristics, and clinical outcomes
including locoregional failure and survival were recorded.
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Commission on Cancer staging system TNM 7th and 8th
editions.23,24Treatment
All treatment was delivered according to the UK IMRT
guidance document.25 Full details are available at www.
analimrtguidance.co.uk. In summary, all patients are
treated supine; as such, the buttocks usually provide bolus to
the anal verge, and in patients with disease infiltrating into
the skin a Pyrex sheet is placed under the patient to provide
build-up. All treatments were delivered in 28 fractions, with
T1/2 N0 receiving 50.4 Gy to the gross primary tumor and
T1/2 Nþ or T3/4 Nany receiving 53.2 Gy.
Involved nodes received 50.4 Gy if <3 cm and 53.2 Gy
if >3 cm; uninvolved pelvic nodes (CTV_Elective)
including mesorectal, obturator, external and internal iliac,
inguinal, and presacral received 40 Gy since March 2014
(previously 39.2 Gy). The ischiorectal fossa (IRF) was only
included in the prophylactic dose level if the tumor
involved the IRF on MRI. The superior margin of the
CTV_Elective was 20 mm above the inferior aspect of the
sacroiliac joint or 15 mm above the most superior site of
gross tumor, whichever was most superior. Total margin
from primary tumor gross tumor volume to planning target
volume was 2.5 cm, reduced in 2016 in early node negative
tumors to 2.0 cm. The clinical target volume (CTV) to
planning target volume for the elective volume was 10 mm
until April 2016 and 5 mm thereafter.
Treatment was delivered using inverse planned simul-
taneous integrated boost technique delivered with coplanar
beams or arc delivery as per ICRU 83. An advanced
convolution superposition algorithm was used. Suggested
IMRT beam positions and optimal and mandatory con-
straints are detailed in the guidance.25 The guidance sug-
gests mitomycin-c 12 mg/m2 day 1 with either capecitabine
825 mg/m2 twice dialy on days of RT or 5-fluorouracil 1000
mg/m2 on days 1 to 4 and 29 to 32. The verification pro-
tocol, which is detailed in the guidance, is daily online
imaging with cone beam CT days 1 to 5 and weekly with
orthogonal paired kV or MV images on all other days.
After completion of CRT, all patients underwent a
physical examination at 3 months and regularly thereafter
until complete response (CR) or a decision on salvage
surgery was made. At least 1 MRI scan was performed to
confirm radiologic CR at 3 months. Patients underwent
clinical examinations every 3 months for 2 years, every 6
months for year 3, and in some centers yearly until 5 years.
CTwas typically done annually at the end of years 1, 2, and
3. Any concerns regarding symptoms or clinical examina-
tion would prompt further investigations. Anoscopy was
not routinely performed as part of follow-up in any of the
centers. Biopsy to confirm recurrence was performed when
a salvage abdominoperineal resection (APR) was planned.Metastatic recurrence was diagnosed on radiologic
evidence.
Data processing
CR was defined as the absence of disease within the irra-
diated volume at 6 months based on clinical, radiologic,
and pathologic examination. Persistent disease was failure
to achieve CR.
Locoregional recurrence (LRR) includes all failures at
site of primary tumor, within the pelvis or inguinal nodes,
with or without distant failure, including both patients who
failed to achieve CR at 6 months and those occurring more
than 6 months after completion of CRT after initial CR.
Local failure was defined as persistence or recurrence at the
site of initial primary tumor and regional failure as
persistence or recurrence elsewhere in the pelvis or inguinal
nodes at any point. The site of failure was determined based
on physical examination, imaging, and pathology. The
relationship between RT volume and location of recurrence
was determined by comparison between CT plans and
diagnostic imaging.
Distant relapse was defined as development of disease
outside of the pelvis or inguinal nodes independent of
locoregional status at any point. Failure within the common
iliac nodes was considered distant failure.
Disease-free survival was calculated in all patients, with
an event defined as either a failure to achieve CR at 6
months or subsequent relapse (local, regional, or distant).
An interruption in RT treatment was defined as any
extension to the treatment >2 days over the planned overall
treatment time, as per RCR guidance.26
Time to failure was the interval from start of CRT to date
of detection of recurrence. Last follow-up was considered
the last clinic visit or date of death.
Statistical analysis
Statistical analysis was carried out using IBM SPSS for
Mac (version 25; SPSS Inc, Chicago, IL) and R (version
3.5.2; R Core Team, R Foundation for Statistical
Computing, Vienna, Austria), and figures were produced
using Microsoft Excel for Mac (version 15.33).
Three-year disease-free survival and overall survival
were estimated by Kaplan-Meier methods. Cox propor-
tional hazards regression analysis was performed to identify
significant predictors of time to locoregional and distant
recurrence, disease-free survival, and overall survival. Lo-
gistic regression analysis was performed to identify sig-
nificant predictors of persistent disease at 6 months. The
predictors used were age, sex, performance status, T stage,
N stage (TNM 7 and 8), failure to complete RT as planned
and type of chemotherapy. It was not possible to include
HIV status in the analysis because almost 40% of patients
in our cohort were not tested. All analyses were run as
univariable tests and multivariable models. There was a
small, time-dependent effect relating to RT completion, but
it was not possible to include this as a time-varying
Table 1 Patient and tumor characteristics (n Z 385)
n (% of total)
Sex
Male 112 (29.1)
Female 273 (70.1)
Age, y
Median 62
Range 29-88
HIV
Positive 16 (4.2)
Negative 220 (57.1)
Not tested 149 (38.7)
Performance status
0 212 (55.1)
1 141 (36.6)
2 19 (4.9)
3 6 (1.6)
Not documented 7 (1.8)
T stage
Tx 1 (0.3)
T1 46 (11.9)
T2 174 (45.2)
T3 92 (23.9)
T4 72 (18.7)
N stage (TNM 7)
Nx 1 (0.3)
N0 185 (48.1)
N1 72 (18.7)
N2 66 (17.1)
N3 61 (15.8)
N stage (TNM 8)
Nx 1 (0.3)
N0 185 (48.1)
N1a 168 (43.6)
N1b 1 (0.3)
N1c 30 (7.8)
M stage
Mx 3 (0.8)
M0 382 (99.2)
Stage grouping (TNM 7&8)
1 38 (9.8)
2 124 (32.2)
3 221 (57.4)
x 2 (0.5)
Radiation therapy
Temporarily interrupted* 12 (3.1)
Prematurely stoppedy 8 (2.1)
Delivered as planned 365 (94.8)
Chemotherapy interrupted or stopped
Yes 41 (10.9z)
No 335 (89.1z)
* Radiation therapy was subsequently continued to full dose.
y Total dose not delivered.
z Percentage of total number of patients who had chemotherapy
(n Z 376).
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complete RT. For chemotherapy type, very few patients had
single-agent treatments; these were therefore combined into
a single category. For multivariable models, nodal status
from TNM 7 was used in preference to TNM 8 because of
the wider distribution of factor levels (only 1 patient had
nodal status 1b). All patients were included in all models.
For analyses where death was the endpoint, patients were
censored at last known follow-up. For analyses of recur-
rence, patients were censored at last known follow-up or
death.
A P value of <.05 was considered statistically
significant.
Governance approval
In accordance with UK practice for health care audits,
approval for data collection was obtained locally by each
contributing site’s Divisional Governance committee.
Results
Three hundred eighty-five consecutive patients meeting the
inclusion criteria were identified. Patient and tumor char-
acteristics are shown in Table 1. All data fields were
complete aside from performance status in 7, which was
not documented at presentation.
All patients were treated with definitive RT, according to
UK IMRT guidance. Table EA (available at https://doi.org/
10.1016/j.ijrobp.2019.10.016) details the treatment deliv-
ered. Fifteen patients did not receive doublet chemotherapy
owing to comorbidities, poor performance status, or patient
choice. Treatment was temporarily interrupted in 12 pa-
tients (intercurrent illness [5], cytopenias [4], sepsis [1],
emergency hernia repair [1], and compliance [1]) and
stopped prematurely in 8 (small bowel obstruction [2],
treatment toxicity [2], patient choice [2], unrelated inter-
current illness [1], and death from neutropenic sepsis [1]).
One patient died during treatment (of neutropenic
sepsis), and 3 died within 6 months of completion of
treatment (complications of chronic renal disease, pneu-
mocystis with unknown HIV status, and pneumonia on a
background of chronic obstructive pulmonary disease).
The median follow-up interval for survivors was 24.0
months (range, 2.0-59.7).
Treatment outcomes
Figure 1 illustrates the outcomes at 6 months post-CRT.
Three hundred thirty-four patients (86.7%) achieved CR
within 6 months of completing CRT. Disease recurrence at
any point during follow-up occurred in 74 patients (19.2%).
This included all persistent disease at the site of the primary
tumor, within the pelvis or inguinal nodes, or subsequent
development of new local, regional, or distant disease after
a CR. The 3-year LRR was 19.5%, and 3-year distant
relapse rate was 10.9%. The location of the first site of
relapse is shown in Table 2. A summary of all patients withpersistent or recurrent disease is available in supplementary
materials, Table EB. (available online at https://doi.org/10.
1016/j.ijrobp.2019.10.016).
334 patients
CR at 6 months
385 patients
46 patients
No CR at 6 months
1 patient
No imaging as only 7
fractions.
4 patients
Died <6 months
23
Tx with palliative intent
18
Salvage surgery
1 patient
Remains on FU
with continued response
3 patients
Went on to achieve CR
1 patient
Equivocal imaging
(subsequently developed
metastatic disease)
4 patients
Ongoing resolution
Fig. 1. Flow chart of outcomes at 6 months post-completion of chemoradiation therapy.
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The 28 patients with residual tumor who did not receive
salvage surgery did not receive surgery for the following
reasons: inoperable disease (9), disseminated metastatic
disease (7), unfit (4), or declined (2), imaging was
thought to be equivocal because of a significant ongoing
pressure sore (1), evidence of ongoing resolution of
disease (4), death before treatment of residual disease
could be considered (1). Of the responses stating inop-
erable, some were inoperable due to patient factors (eg,
1 patient was unwell with peritumoral sepsis, associated
osteomyelitis, and hydronephrosis due to ureteric
obstruction); most were surgical factors such as diseaseTable 2 Patterns of treatment failure (93 sites of primary
failure in 74 patients)
Site n (% of total failures)
Locoregional* ( distant) 63 (85.1)
Primary site 62 (83.4)
Pelvic nodes 7 (9.5)
Inguinal nodes 5 (6.8)
Perineum 1 (1.4)
Distanty ( locoregional) 30 (40.5)
Lung 17 (23.0)
Liver 13 (17.6)
Distant nodes 13 (17.6)
Common iliacs 3 (4.1)
Paraortic 3 (4.1)
Bone 2 (2.7)
Adrenal 1 (1.4)
Subcutaneous tissues 1 (1.4)
Multiple distant organs 15 (20.3)
* Some patients experienced failures at multiple sites.
y First site of distant failure.outside operative field, either primary extension or nodal
deposits; some were factors demonstrating bad biology
such as new satellite nodules in the right perineum or
persistent inguinal disease.Sites of LRR after CR
Ten patients had isolated local recurrence at first site of
relapse at a median of 17.7 months (range, 10.2-25.8) from
the start of their CRT.
The 3-year incidence for regional recurrence was 14.1%
(95% confidence interval [CI], 8.2-20.0) in patients with
initially uninvolved nodes and 24.7% (95% CI, 18.2-31.2)
in those with involved nodes at outset.
Five patients had regional relapse in nodes that were not
involved at outset in the presence of metastatic disease. One
occurred in a patient with CR at 6 months, and the other 4
occurred in patients who failed to achieve CR at 6 months.
Only 2 patients had regional relapse as first site of relapse
in the absence of concurrent distant relapse. One patient
relapsed in a previously involved left mesorectal lymph
node and the second in a previously involved right inguinal
node. Figure 2 demonstrates the locations of the locore-
gional failures.Distant disease
Overall, 30 patients developed distant disease (7.8%).
The median time to development of distant disease was
14.6 months (range, 8.3-32.7) from the start of CRT.
Distant metastases occurred in 13 of the 46 (28.3%)
patients who failed to achieve a CR 6 months after CRT,
compared with 17 of the 334 (5.1%) patients with a CR
at 6 months.
Each circle represents a site of
locoregional recurrence. Circle colour
represents the type of relapse. Text
indicates the RT dose (Gy) received at
that site. Details of local failures given
below.
Abbreviations: AP = anteroposterior, DRR = 
digitally reconstructed rediograph, RT = 
radiotherapy.
Local failures:
53.2 x 4
50.4 x 1
50.4 x 1
Fig. 2. Representative plain kV films with locations of failure superimposed. All locoregional disease excluding persistent
disease at the primary site is depicted.
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Eighteen of the 46 patients with documented incomplete
response (39.1%) underwent salvage APR. Twelve of the
18 remained cancer free for the remainder of follow-up.
Of the 10 patients who had an isolated local recurrence
after a documented CR to CRT, 8 underwent salvage APR.
Seven achieved an R0 resection and remained cancer free
for the remainder of follow-up. Two patients were treated
with palliative intent due to patient choice and poor tumor
biology.
One of the 2 patients with regional relapse in the
absence of distant disease underwent salvage APR; how-
ever, this patient died of metastatic disease 11 months
postsurgery.
Survival
There were a total of 47 deaths from any cause, including
36 (9.4%) from ASCC. Figure 3 shows Kaplan-Meier
curves for disease-free and overall survival. Three-year
overall survival was 85.6% (95% CI, 81.1-90.1), and 3-
year disease-free survival was 75.6% (95% CI, 70.5-
80.7). Median disease-free and median overall survival
time were not reached due to relatively short follow-up.
The 3-year colostomy-free survival was 69.0% (95% CI,
63.1-74.1%).
Predictors of outcome
Predictive factors for locoregional relapse included male
sex, high N-stage, and failure to complete RT as planned(Table 3). To take the competing risk of death into account,
we calculated the cumulative incidence of LRR.27 There
was a negligible difference in the estimates between the
methods: Using the Kaplan-Meier method, the incidences
at 12, 24, and 36 months, respectively, were 15.1%, 18.6%,
and 19.7% compared with 15.0%, 18.5%, and 19.6% using
the cumulative incidence method.
Three-year locoregional relapse for the 2 main chemo-
therapy regimens used was 19.0% (95% CI, 12.3-25.7) for
mitomycin/capecitabine and 19.7% (95% CI, 15.6-23.8) for
mitomycin/5-fluorouracil (5FU). Three-year distant relapse
was 11.0% (95% CI, 4.7-17.3) and 7.1% (95% CI, 3.0-11.2)
for mitomycin/capecitabine versus mitomycin/5FU,
respectively. Lastly, the 3-year DFS between the 2 regimens
was 81.0% (95% CI, 73.9-88.1) and 81.9% (95% CI, 76.0-
87.8) in favor of mitomycin/5FU.
Predictors for other outcomes (distant relapse, persistent
disease, disease-free and overall survival) were similar and
are available in the supplementary materials (Tables EC to
EF available online at https://doi.org/10.1016/j.ijrobp.2019.
10.016).
Discussion
To the best of our knowledge, this is the only series
reporting patterns of failure after IMRT and the largest
published series of IMRT examining outcomes. It should
serve as a valuable resource for the future optimization of
IMRT and the development and design of future trials
incorporating IMRT.
The disease outcomes from IMRT outlined here are
equivalent to those published from 3D conformal RT. Our
reported CR rate (86.7%) is similar to the 90% seen in the
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Fig. 3. Disease-free (a) and overall (b) survival with confidence intervals.
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Table 3 Predictors of locoregional recurrence (n Z 385)
Variable Value
Univariable Multivariable
Hazard ratio (CI) P Hazard ratio (CI) P
Age Per year 1.01 (0.99-1.04) .252 1.02 (0.99-1.04) .187
Sex Female Reference Reference
Male 1.78 (1.09-2.91) .021 2.08 (1.24-3.48) .005
Performance status 0 Reference Reference
1 1.90 (1.14-3.19) .014 1.31 (0.75-2.28) .341
2 2.09 (0.73-5.98) .169 1.27 (0.40-4.00) .680
3 3.53 (0.84-14.93) .086 2.78 (0.60-12.90) .192
T stage 1 Reference Reference
2 1.67 (0.50-5.66) .407 1.26 (0.37-4.36) .712
3 4.13 (1.23-13.79) .021 2.54 (0.72-8.95) .148
4 5.17 (1.55-17.28) .008 2.87 (0.81-10.17) .102
x 0 (0-N) .996 0 (0-N) .998
N stage (TNM 7) 0 Reference Reference
1 2.24 (1.19-4.26) .013 2.23 (1.13-4.39) .021
2 1.37 (0.64-2.90) .416 0.79 (0.34-1.82) .576
3 3.05 (1.63-5.73) <.001 1.85 (0.91-3.75) .088
x 0 (0-N) .996 0 (0-N) .998
N stage (TNM 8) 0 Reference
1a 2.17 (1.28-3.71) .004
1b 0 (0-N) .997
1c 2.19 (0.93-5.14) .073
x 0 (0-N) .996
RT completion Completed as planned Reference Reference
Incomplete or interrupted* 5.29 (2.83-9.90) <.001 4.96 (2.40-10.27) <.001
Chemotherapy MMC 5FU Reference Reference
MMC capecitabine 0.92 (0.56-1.51) .747 0.95 (0.56-1.58) .830
Single agent 1.24 (0.17-9.03) .833 1.91 (0.25-14.62) .532
None 0.71 (0.10-5.15) .732 0.57 (0.07-4.57) .597
Abbreviations: 5FU Z 5-fluorouracil; CI Z 95% confidence interval; MMC Z mitomycin-c; RT Z radiation therapy.
* An interruption in radiation therapy was defined as any extension more than 2 days over the planned overall treatment time.
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treated in clinical trials.11 Our 3-year DFS (75.6%) is
similar to the 73% reported in ACT2, and our overall sur-
vival (85.6%) is comparable with that in RTOG 9811,
ACCORD, and ACT2 at 78%, 74%, and 85%, respec-
tively.9-11
Comparison to other smaller IMRT series is difficult
owing to the varying outcome definitions; however, 2-year,
3-year, and 4-year DFS is reported as 84.4%, 71%, and
82% in smaller published series.28-31 In terms of patterns of
relapse we can compare to the 4 retrospective cohorts of a
3D conformal technique, acknowledging that these publi-
cations reported different outcomes and definitions of out-
comes.32-35 Our LRR (19.5%) is similar to the 14.4% to
25% presented in these papers. In terms of percentage of all
recurrences, our primary tumor recurrence rate (83.4%)
was higher than in previous publications (40.9%-53.8%);
however, both our pelvic relapse (9.5%) and inguinal
relapse rate (6.8%) are at the lower end of what was pre-
viously reported. Possible hypotheses for this low pelvic
relapse are as follows: 2 of the previous studies did not
routinely include the inguinal nodes in the prophylacticvolume, whereas our guidance advocates that all high-risk
T1 and T2 disease should undergo prophylactic inguinal
irradiation; the increased homogeneity of coverage of at
risk lymph nodes with IMRT; and finally, the increased
routine use of 18-fluorodeoxyglucose PET results in more
involved nodes than previously. Tumor control probability
modeling data suggest higher doses result in improved
tumor control36; therefore, if we are finding more involved
nodes and delivering a higher boost dose to them, this may
lower regional relapse rates.
Our rate of distant relapses (7.8%) is lower than those
previously reported. This may be due to the improved
staging at outset with PET or short follow-up. The
increased distant metastasis rate in those with an incom-
plete response after CRT may suggest this group with
radioresistant disease is a different biological subgroup and
continued interrogation of tumor biology is required.37
Consistent with Bentzen et al,35 a substantial proportion
of those with residual tumor were not candidates for
salvage surgery. Previous series have shown that a signifi-
cant proportion of patients who have salvage surgery sub-
sequently relapse and ultimately die of ASCC.35 Our data
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alive and free from disease. Accepting limited follow-up
and more sophisticated assessment of occult metastatic
disease (with PET), the high R0 resection rate indicates
good preoperative assessment and surgical approach.
Some insight can be gained into the dose used for pro-
phylactic nodes. We delivered 40 Gy in 28 fractions, which
is a biologically equivalent dose equivalent to 30.6 Gy in 17
fractions delivered in the ACT2 trial. For calculations we
used an alpha-beta ratio of 8 and a loss of 0.7 Gy per day
after 20 fractions.38 With this dose, there were only 2 re-
lapses in regional nodes in the absence of metastatic dis-
ease. Both occurred in nodes that were present and boosted
at outset. Internationally there has been a move to deliver
much higher prophylactic doses to the noninvolved nodes.
Our series suggests that 40 Gy in 28 fractions is sufficient
to prevent regional disease in prophylactic nodal groups.
In terms of informing IMRT delineation, an area of
controversy is whether to include the IRF in the prophy-
lactic volume. UK guidelines only include the IRF when
disease is there at outset. This would appear sufficient
considering there was 1 perineal relapse, in a patient who
had T4 disease at outset, which may have included the IRF.
The superior border is another area of uncertainty and
differs between protocols. With our superior border, we had
no relapses in internal iliac/external iliac nodes above our
border, in the absence of widespread metastatic disease.
A further observation was made regarding the new TNM
8 classification. In our series only 1 case fulfilled the N1b
criteria. Although the differentiation between N0 and N1a
or N1c was very predictive, the number of patients within
N1b suggests this criterion may be of limited use or diffi-
cult to validate.
The results of the predictive factors are in keeping with
literature to date other than the lack of T stage affecting
DFS or local relapse on multivariant analysis.32,33 The
authors found it hard to identify a hypothesis for this
finding. It may be that T stage in historic papers was
associated with regional nodal relapse and because this
occurred less in this series it is no longer predictive. Further
work would be required to identify whether this is a true
finding. The correlation of N stage with distant recurrence
may warrant further investigation into newer chemothera-
peutic, immunotherapeutic, and targeted agents in patients
with node-positive ASCC, such as the CORINTH study, a
phase 1 trial investigating the use of pembrolizumab
concurrently with CRT: (EudraCT 2017-002300-27) and
the adjuvant nimvolumab study (NCT03233711).
The almost identical LRR and DFS for the 2 different
main chemotherapy regimens used is a similar finding to
that published using the data from the UK anal cancer
audit.39 The significantly poorer outcomes experienced by
patients who failed to complete RT as planned emphasizes
the importance of close monitoring and management of
toxicities during treatment.
Our study has limitations. It was performed retrospec-
tively, based on data collected from hospital records.Despite this we have collected all data, excluding 1.8% of
performance status. A number of patients (38.7%) were not
tested for HIV because this was not routine in all centers at
the time of treatment. Unfortunately, human papillomavirus
testing was not performed in any of the centers over this
period, so we cannot comment on this. As mentioned in the
Methods and Materials section, the different centers had
different thresholds of use for PET. The center that per-
formed PET scans on all T2 patients contributed 28.3% of
the patients, and the center that had no access contributed
18.4% of all patients. The other 3 centers with selective use
of PET scanning contributed 53.2% in total. Hence,
although PETwas not standard it was used in a larger cohort
of patients than in previous studies, likely affecting results
as mentioned throughout the Discussion. Our series did not
involve quality assurance of RT planning or delivery, so
adherence to the guidance cannot be guaranteed. However
all 5 centers involved were involved in a number of meet-
ings to design the guidance. Once published, there were
further meetings to advertise and disseminate the guidance
and finally contouring workshops over this period in the run
up to the PLATO study. At all of these points, contours were
reviewed and discussed. Four of the centers were involved
in delineating the gold standard for use in Radiotherapy
Trials Quality Assurance in PLATO, and 3 were centers that
provide contour review for PLATO study. Different strate-
gies for identification and management of toxicities in
different centers could have affected completion rates and
subsequently outcomes. Unfortunately, due to the different
populations in the different centers, the authors believed an
analysis between centers would have too many confounding
factors. There is the possibility of some patient selection at
the level of each center.
It must be acknowledged that these patients were treated
with the IMRT delivery according to UK guidance and as
such results are not applicable to other doses, volumes, and
constraints.
Some caution is required in interpreting the outcomes of
treatment due to the relatively short follow-up, 2 years
compared with 4 for other series.32-35 A number of our
patients (45.5%) have <2 years follow-up. Long-term
outcome evaluations have previously shown that 84% of
failures after CRT for ASCC occur in the first 2 years40 and
94% by 3 years.41 Whether the pattern of late relapse is
different from the pattern of early relapse has not previ-
ously been studied and similarly cannot be answered by this
series. However, late relapses are rare, so the authors
believe these data offer a useful focus for further research
and development.
In terms of statistical analysis, although for this rare
tumor type we have achieved a large data set, for statistical
purposes it is relatively small based on the number of events
for each outcome. These predictive models should therefore
be interpreted with caution because they are underpowered
for the intended number of variables for testing.
The toxicity of treatment is not addressed by our series.
The acute toxicity of our guidance has been previously
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ment is a factor we did not investigate owing to the limi-
tations of retrospective reviews of late toxicity. Work is
ongoing with the UK anal cancer audit to analyze pro-
spectively gathered late toxicity using Patient Reported
Outcome Measures, which we hope will contribute signif-
icantly to this important question.
Lastly, there are significant difficulties in comparison
across trials stemming from the varying outcome defini-
tions. We defined our clinical outcomes with advice from
the CORMAC team, who recently published a core set of
outcomes in ASCC42 with the inclusion of the additional
outcome colostomy-free survival due to international in-
terest in this outcome. The CORMAC group undertook a
systematic review of anal cancer trials, identifying 1192
different anal cancer outcomes. Subsequent to this they
published international patient and health care professional
consensus outcomes. Although the definitions of these
outcomes are not agreed on, we have acknowledged the
CORMAC group, who assisted in the definition of the
outcomes reported. These are also in keeping with the
ongoing PLATO trial.43
The IMRT guidance was developed in the run up to the
PLATO trial, which is a platform of studies for ASCC using
the UK IMRT guidance as a backbone for RT delivery. The
patterns of recurrence reported here support the rationale of
the ACT5 trial. It evaluates whether dose escalation to the
sites of gross tumor reduces locoregional failure.
Conclusions
This series provides much-needed data on the patterns of
relapse after IMRT in ASCC. We believe this series sup-
ports the use of the UK IMRT guidance in routine clinical
care. The lower prophylactic nodal dose of 40 Gy in 28
fractions is sufficient to prevent isolated regional relapse in
uninvolved nodes. Due to the high rate of relapse at the
primary site, strategies to optimize the radiation response,
such as dose escalation, immune modulation, or radio-
sensitization, are most likely to have an impact on disease-
free survival and overall survival.
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